proline and Encephalopathy, Toxic

proline has been researched along with Encephalopathy, Toxic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bui, LA; Clary, DO; Cortes, J; Kantarjian, H; Olszynski, P; Shah, NP; Smith, CC; Sokol, L; Song, C; Tam, CS; Verstovsek, S; Wadleigh, M	1
Bugg, CW; Dunn, DE; Khoshnan, A; Lo, DC; Patterson, PH; Southwell, AL	1
Aghajanov, M; Bosker, F; Gladkevich, A; Korf, J; Vahradyan, H; Yenkoyan, K	1

Reviews

1 review(s) available for proline and Encephalopathy, Toxic

Article	Year
Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders -- therapeutic potential or a mirage? Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7 Topics: Alzheimer Disease; Animals; Caspases; Clinical Trials as Topic; Cognition; Crush Syndrome; Humans; Hypothalamus; Immunity; Intercellular Signaling Peptides and Proteins; Neurodegenerative Diseases; Neurotoxicity Syndromes; Oxidative Stress; Peptides; Pituitary Gland; Proline	2007

Article

Year

Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders -- therapeutic potential or a mirage?

Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7

Topics: Alzheimer Disease; Animals; Caspases; Clinical Trials as Topic; Cognition; Crush Syndrome; Humans; Hypothalamus; Immunity; Intercellular Signaling Peptides and Proteins; Neurodegenerative Diseases; Neurotoxicity Syndromes; Oxidative Stress; Peptides; Pituitary Gland; Proline

2007

Trials

1 trial(s) available for proline and Encephalopathy, Toxic

Article	Year
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia research, 2014, Volume: 38, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Drug Monitoring; Early Termination of Clinical Trials; Female; Humans; Janus Kinase 2; Male; Middle Aged; Neurotoxicity Syndromes; Primary Myelofibrosis; Proline; Protein Kinase Inhibitors; Pyrimidines	2014

Article

Year

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Leukemia research, 2014, Volume: 38, Issue:3

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Drug Monitoring; Early Termination of Clinical Trials; Female; Humans; Janus Kinase 2; Male; Middle Aged; Neurotoxicity Syndromes; Primary Myelofibrosis; Proline; Protein Kinase Inhibitors; Pyrimidines

2014

Other Studies

1 other study(ies) available for proline and Encephalopathy, Toxic

Article	Year
Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Sep-03, Volume: 28, Issue:36 Topics: Animals; Antibodies; Antibody Specificity; Brain; Cell Line, Transformed; Disease Models, Animal; Epitope Mapping; Humans; Huntingtin Protein; Immunoglobulin Variable Region; In Vitro Techniques; Luminescent Proteins; Mutation; Nerve Tissue Proteins; Neurotoxicity Syndromes; Nuclear Proteins; Penicillamine; Peptides; Proline; Protein Binding; Protein Structure, Tertiary; Transfection	2008

Article

Year

Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.

The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Sep-03, Volume: 28, Issue:36

Topics: Animals; Antibodies; Antibody Specificity; Brain; Cell Line, Transformed; Disease Models, Animal; Epitope Mapping; Humans; Huntingtin Protein; Immunoglobulin Variable Region; In Vitro Techniques; Luminescent Proteins; Mutation; Nerve Tissue Proteins; Neurotoxicity Syndromes; Nuclear Proteins; Penicillamine; Peptides; Proline; Protein Binding; Protein Structure, Tertiary; Transfection

2008